Literature DB >> 18574267

New antithrombotic drugs: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition).

Jeffrey I Weitz1, Jack Hirsh2, Meyer M Samama3.   

Abstract

This chapter focuses on new antithrombotic drugs that are in phase II or III clinical testing. Development of these new agents was prompted by limitations of existing antiplatelet, anticoagulant, or fibrinolytic drugs. Addressing these unmet needs, this chapter (1) outlines the rationale for development of new antithrombotic agents, (2) describes the new antiplatelet, anticoagulant, and fibrinolytic drugs, and (3) provides clinical perspectives on the opportunities and challenges faced by these novel agents.

Entities:  

Mesh：

Substances：

Year:  2008        PMID： 18574267     DOI： 10.1378/chest.08-0673

Source DB:  PubMed          Journal:  Chest        ISSN： 0012-3692            Impact factor:   9.410


  38 in total

Review 1.  Limitations of conventional anticoagulant therapy and the promises of non-heparin based conformational activators of antithrombin.

Authors:  Qudsia Rashid; Poonam Singh; Mohammad Abid; Mohamad Aman Jairajpuri
Journal:  J Thromb Thrombolysis       Date:  2012-08       Impact factor: 2.300

Review 2.  Benefit-risk assessment of dabigatran in the treatment of stroke prevention in non-valvular atrial fibrillation.

Authors:  Sascha Meyer Dos Santos; Sebastian Harder
Journal:  Drug Saf       Date:  2014-05       Impact factor: 5.606

3.  New direct thrombin inhibitors.

Authors:  Alessandro Squizzato; Francesco Dentali; Luigi Steidl; Walter Ageno
Journal:  Intern Emerg Med       Date:  2009-09-15       Impact factor: 3.397

4.  A 1-year drug utilization evaluation of protamine in hospitalized patients to identify possible future roles of heparin and low molecular weight heparin reversal agents.

Authors:  Charles E Mahan
Journal:  J Thromb Thrombolysis       Date:  2014-04       Impact factor: 2.300

Review 5.  New anticoagulants: pharmacology and clinical studies.

Authors:  Charles Marc Samama
Journal:  Wien Med Wochenschr       Date:  2011-02

6.  [New perspectives on oral preventive anticoagulants].

Authors:  Belén Enfedaque Montes; Elisenda Sant i Arderiu
Journal:  Aten Primaria       Date:  2010-02-01       Impact factor: 1.137

Review 7.  Update on heparin: what do we need to know?

Authors:  Daniel S Weitz; Jeffrey I Weitz
Journal:  J Thromb Thrombolysis       Date:  2010-02       Impact factor: 2.300

Review 8.  Anticoagulant therapy with the oral direct factor Xa inhibitors rivaroxaban, apixaban and edoxaban and the thrombin inhibitor dabigatran etexilate in patients with hepatic impairment.

Authors:  Jochen Graff; Sebastian Harder
Journal:  Clin Pharmacokinet       Date:  2013-04       Impact factor: 6.447

Review 9.  Newer anticoagulants in 2009.

Authors:  Meyer Michel Samama; Grigoris T Gerotziafas
Journal:  J Thromb Thrombolysis       Date:  2010-01       Impact factor: 2.300

Review 10.  Novel oral anticoagulants: clinical pharmacology, indications and practical considerations.

Authors:  Sebastian Harder; Jochen Graff
Journal:  Eur J Clin Pharmacol       Date:  2013-04-26       Impact factor: 2.953
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.